Alec Stranahan
Stock Analyst at B of A Securities
(0.78)
# 4,007
Out of 5,090 analysts
32
Total ratings
40%
Success rate
-27.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $234.13 | +8.91% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.33 | +31.33% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $17.30 | -30.64% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $3.27 | -69.42% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $6.91 | +1.30% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $27.09 | +55.04% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.92 | +215.66% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.90 | +478.95% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.40 | +150.00% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.42 | +519.83% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $79.64 | -30.94% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $30.76 | -80.49% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $234.13
Upside: +8.91%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.33
Upside: +31.33%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $17.30
Upside: -30.64%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $3.27
Upside: -69.42%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $6.91
Upside: +1.30%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $27.09
Upside: +55.04%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.92
Upside: +215.66%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.90
Upside: +478.95%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.40
Upside: +150.00%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.42
Upside: +519.83%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $79.64
Upside: -30.94%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $30.76
Upside: -80.49%